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Infiltration of cytotoxic T-lymphocytes in ovarian cancer is a favorable prognostic factor. Employing a differential expression
approach, we have recently identified a number of genes associated with CD8+ T-cell infiltration in early stage ovarian tumors. In
the present study, we validated by qPCR the expression of two genes encoding the transmembrane proteins GPC6 and TMEM132D
in a cohort of early stage ovarian cancer patients. The expression of both genes correlated positively with the mRNA levels of
CD8A, a marker of T-lymphocyte infiltration [Pearson coefficient: 0.427 (𝑝 = 0.0067) and 0.861 (𝑝 < 0.0001), resp.]. GPC6 and
TMEM132D expression was also documented in a variety of ovarian cancer cell lines. Importantly, Kaplan-Meier survival analysis
revealed that high mRNA levels of GPC6 and/or TMEM132D correlated significantly with increased overall survival of early stage
ovarian cancer patients (𝑝 = 0.032). Thus, GPC6 and TMEM132Dmay serve as predictors of CD8+ T-lymphocyte infiltration and
as favorable prognostic markers in early stage ovarian cancer with important consequences for diagnosis, prognosis, and tumor
immunobattling.
1. Introduction
Despite the slight decrease in the incidence and death rates
of ovarian cancer over the recent years, it remains the
major cause of death due to gynecological malignancies.
About 22,000 new cases and 14,000 deaths are expected in
the United States alone in 2014 [1]. Because of the lack of
obvious and specific symptoms at the onset of the disease,
the majority of the cases are diagnosed at a late stage. The
five-year overall survival rate of ovarian cancer patients is
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approximately 44%. On the contrary, patients with early
stage ovarian cancer exhibit significantly higher survival
rates [2]. The age at the time of diagnosis, the stage of
the disease, the histological subtype, and tumor grade are
common prognostic factors used to predict clinical outcome
[3]. Similarly, the expression levels of several genes have
been found to correlate with patients’ survival [4–7]. For
instance, patients with low/intermediate levels of BRCA1
mRNA exhibit higher overall survival following treatment
with platinum-based chemotherapy compared to patients
with high levels of BRCA1mRNA [8]. Thus, characterization
of molecular markers with prognostic value is of great impor-
tance in order to stratify high-risk ovarian cancer patients and
implement the most appropriate therapeutic scheme.
Similar to several other types of solid cancers, ovarian
tumors are immunogenic with various immune cell popula-
tions infiltrating the tumor sites. Zhang et al. demonstrated
that intratumoral infiltration of CD3+ T-lymphocytes cor-
relates significantly with high progression-free and overall
survival of ovarian cancer patients [9]. Since then, a number
of studies have highlighted the prognostic significance of T-
cell infiltration in ovarian cancer [10–13]. For instance, it has
been well documented that infiltration with high numbers
of CD8+ T-lymphocytes associates positively with survival
benefit and favorable clinical outcome [14, 15]. So far, gene
expression profiling by microarrays has been employed by
three independent research groups in order to elucidate the
genes and the underlying molecular mechanisms that govern
T-cell infiltration in ovarian cancer [16–18]. All of these
studies focused on advanced stage ovarian cancer and each
identified a number of differentially expressed genes thatwere
associatedwithCD8+T-lymphocyte infiltration and immune
responses and even with survival [16–18].
Recently, utilizing a fluorescent version of the ADDER
(Amplification of Double-Stranded cDNA End Restriction
Fragments) Differential Display methodology, we identified,
for the first time, genes overexpressed in early stage ovar-
ian cancer which are associated with CD8+ T-lymphocyte
infiltration [19]. For instance, the mRNA levels of one of
the identified genes, SMARCE1, correlated significantly with
the expression of CD8A, a marker of T-cell infiltration.
Importantly, forced overexpression of SMARCE1 in ovarian
cancer cells induced the expression and secretion of certain
chemokines and consequently triggered the chemotaxis of
CD8+ T-lymphocytes in vitro [19].
In the present study, we evaluated the expression of
two other overexpressed genes, GPC6 and TMEM132D, and
investigated whether they could represent novel prognostic
markers of survival in early stage ovarian cancer. We selected
to study these two genes as they are both surface antigens.
TMEM132D is a transmembrane protein, while GPC6 is
a GPI-anchored protein on the outer surface of the cell
which may be cleaved off and released in the extracellular
space.Through the heparan sulfate glycosaminoglycan chains
GPC6 can interact with other molecules and receptors of
the membrane. Moreover, glypicans may regulate Hedgehog,
Wnt, BMP, and FGF signaling pathways. On the contrary, the
exact biological role of TMEM132D still remains quite elusive.
The localization of these proteins suggests that they may be
involved in intercellular signalling and cell-cell recognition,
aspects critical for the mechanisms of cell attraction and
recruitment.We validatedwith qPCR the expression ofGPC6
and TMEM132D in a cohort of stage I-II ovarian cancer
patients. The expression of both genes correlated positively
with the CD8A marker and thus with T-cell infiltration.
Furthermore, the expression of both geneswasmonitored in a
variety of ovarian cancer cell lines. Ultimately, we performed
a retrospective survival analysis of the early stage ovarian
cancer patients and correlated the mRNA levels of GPC6
and TMEM132D with the overall survival. Patients with high
mRNA levels of GPC6 and/or TMEM132D exhibited survival
benefit compared to patients with low mRNA levels of both
genes.
2. Materials and Methods
2.1. Patients and Specimens. Ovarian cancer tumor speci-
mens were obtained frompatients undergoing primary debu-
lking surgery by surgeons within the Gynecologic Oncology
Division at the University of Pennsylvania. The stage of the
disease was determined by the gynecologic oncologists. The
histology and grade of the tumor samples were established
by the surgical pathologist. Specimens were immediately
snap-frozen and stored at −80∘C. The tissue collection
was approved by the IRB committee of the University of
Pennsylvania. The analysis of the samples took place at the
Department of Molecular Biology and Genetics, abiding to
the guidelines of the Ethics Commission of the Democritus
University of Thrace.
2.2. Cell Lines and Culture. Human epithelial ovarian cancer
cell lines SKOV3, OVCAR3, OVCAR5, A1847, A2780, and
C30 were acquired from ATCC and cultured in RPMI
1640 with stable glutamine, supplemented with 10% FBS,
100U/mL penicillin, and 100𝜇g/mL streptomycin (all from
Biosera). Mouse ovarian cancer cell line ID8 was originally
donated by Drs. Kathy Robby and Paul Terranova and
cultured in DMEM high glucose with stable glutamine and
sodium pyruvate (Biosera), supplemented with 10% FBS,
100U/mL penicillin, and 100𝜇g/mL streptomycin. Cell lines
were cultured at 37∘C, 5% CO
2
, in a humidified atmosphere
and passaged for fewer than six months since receipt and
stock thawing.
2.3. RNA Isolation and Reverse Transcription. Total RNAwas
isolated from tissue or from 1 × 106 cells with TRIzol reagent
(Life Technologies). The quality, integrity, and quantity of
the isolated RNA were assessed spectrophotometrically and
by gel electrophoresis. Following treatment with RNase-free
DNase, total RNA was reverse-transcribed using Superscript
First-Strand Synthesis Kit for RT-PCR (Life Technologies)
according to manufacturer’s instructions.
2.4. Quantitative PCR. qPCR was performed on a StepOne
real-time PCR system (Applied Biosystems) using the KAPA
SYBR Fast qPCR kit (KAPA Biosystems) under the following
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conditions: 95∘C/3min and then 40 cycles at 95∘C/15 sec-
onds and at 59∘C/1min. The housekeeping gene b-actin was
employed as internal control for normalization. The primers
for CD8A, GPC6, TMEM132D, and b-actin were as follows:
CD8A forward 5󸀠-CCCTGAGCAACTCCATCA-
TGT-3󸀠 and
reverse 5󸀠-GGCTTCGCTGGCAGGAA-3󸀠,
GPC6 forward 5󸀠-GGGCACAGCAAAGCCAGATA-
3󸀠 and
reverse 5󸀠-TGGTTGGTGAGCCCATCAT-3󸀠,
TMEM132D forward 5󸀠-CACTGGTCGCCGGTA-
CTCAT-3󸀠 and
reverse 5󸀠-GACCTTCCGTCACTTTGGAAAA-3󸀠,
b-actin forward 5󸀠-GCGCGGCTACAGCTTCA-3󸀠
and
reverse 5󸀠-CTTAATGTCACGCACGATTTCC-3󸀠.
For relative quantification, the formula RQ = 2−(ΔΔCt) was
used. Prior to using the ΔΔCt method for relative quanti-
fication of the transcripts, validation experiments were per-
formed by applying the relative standard curve method in
order to demonstrate that the PCR efficiencies of the targets
CD8A,GPC6, and TMEM132D and of the housekeeping gene
b-actin were approximately equal. In general, each reaction
was run in triplicate and each PCR experiment included two
nontemplate controls.
2.5. ADDER Fluorescent Differential Display. ADDER was
adapted from [20] for fluorescent detection as previously
described [19].
2.6. Immunohistochemistry. Paraffin embedded tissue sam-
ples from ovarian tumors were available from patients
who underwent surgery. Four-micron sections (4 𝜇m) of
representative blocks from each case were deparaffinized,
rehydrated, and treated with 0.3% H
2
O
2
for 5min in
methanol to prevent endogenous peroxidase activity and
were immunostained by the peroxidase method (Envision
System, DAKO, Carpinteria, California, USA) according to
the manufacturer’s recommendations. After antigen retrieval
and endogenous peroxidase blockade, the sections were
incubated overnight at 4∘Cwith polyclonal antibodies against
Glypican-6 (Acris, Germany) and TMEM132D (Novus Bio,
USA) in 1 : 100 and 1 : 80 dilutions, respectively.Then, the sec-
tions were incubated with secondary antibody at room tem-
perature for 60min. Finally, bound antibody complexes were
stained for 10min with 0.05% diaminobenzidine. Sections
were then briefly counterstained with Mayer’s haematoxylin,
mounted, and examined under a Nikon Eclipse 50i micro-
scope. Control slides were incubated for the same periodwith
nonimmunized rabbit serum (negative control). A positive
control was always run in the assay. The staining results were
evaluated by a pathologist based on the percentage of staining
in tumor cells.
2.7. Statistical Analysis. Graphs and statistical analysis of the
data were performed with GraphPad Prism 5 and SPSS ver-
sion 19.0. Correlation of GPC6 and TMEM132 mRNA levels
with CD8A expression levels was examined by Pearson coef-
ficient correlation. The chi-square test was used to assess the
association of the expression levels of GPC6 and TMEM132D
with patients’ clinicopathologic characteristics (stage, grade,
and histotype). To study whether mRNA levels of GPC6
and TMEM132Dwere predictive for overall survival, survival
rates were calculated with the Kaplan-Meier method and the
statistical difference between survival curves was determined
with the log-rank test. Overall survival was defined as the
time interval from diagnosis/first surgery to death or last
follow-up. Multivariate Cox proportional hazards regression
analysis was performed in order to evaluate the independent
effect of GPC6 and TMEM132DmRNA levels on overall sur-
vival. Multivariate regression models included stage, grade,
histotype, and CD8A mRNA levels. All tests were two-tailed
and statistical significance was considered for𝑝 values < 0.05.
3. Results
By employing a fluorescent version of ADDER Differential
Display, we have recently reported the identification of 128
genes overexpressed in early stage ovarian tumors enriched
with CD8+ T-lymphocytes (TIL+ tumors) [19]. GPC6 and
TMEM132D, encoding for the heparan sulfate proteoglycan
Glypican-6 and the transmembrane protein 132D, respec-
tively, were included in the identified genes (Figures 1(a) and
2(a), resp.). Here, we further evaluated the expression of these
two genes in early stage ovarian cancer.
3.1. GPC6 and TMEM132D Are Differentially Expressed in
TIL+ Early Stage Ovarian Cancer and Their Expression
Levels Correlate with CD8+ T-Cell Infiltration. In order to
validate the expression of GPC6 and TMEM132D in early
stage ovarian cancer, we measured by qPCR their mRNA
levels in tumor samples from 38 stage I-II ovarian cancer
patients (Figures 1(b) and 2(b), resp.). The expression of
both genes was detectable in all patient samples analyzed, at
various levels. To investigate whether GPC6 and TMEM132D
expression correlates with CD8+ T-lymphocyte infiltration
in early stage ovarian cancer, we used qPCR to quantify
the mRNA levels of the CD8A marker in the same cohort
of patients. Interestingly, a statistically significant positive
correlation between themRNA levels ofGPC6 orTMEM132D
and CD8A accordingly was observed (Figures 1(c) and 2(c),
resp.). Thus, the mRNA expression levels of GPC6 and
TMEM132D correlate with CD8+ T-lymphocyte infiltration
in early stage ovarian cancer. Moreover, we quantified by
qPCR the relative expression of GPC6 and TMEM132D in
a variety of ovarian cancer cell lines and demonstrated
that the expression of both genes is not restricted to the
infiltrating immune cells and may actually originate from the
tumor cells. As shown in Figure 1(d), expression of GPC6
was documented in all cell lines tested except one (i.e.,
OVCAR5). Similarly, all ovarian cancer cell lines expressed
TMEM132D (Figure 2(c)). To further validate the expression
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Figure 1: GPC6 is overexpressed in TIL+ early stage ovarian cancer and its expression correlates positively with CD8+ T-lymphocyte
infiltration. (a) GPC6 was overexpressed in the TIL+ ovarian cancer sample as visualized by fluorescent ADDER (band indicated by an
arrow). Lane (+) displays the gene expression profile of the TIL+ sample generated by the corresponding Differential Display primer set;
lane (−) displays the expression profile of the TIL− sample and lane (C) displays the combined profile of equal amount of PCR products of
both samples. Genes expressed equally in both samples appear as yellow bands in lane (C). (b) The expression of GPC6 was quantified by
qPCR in samples derived from 38 stage I-II ovarian cancer patients. The relative expression of GPC6 was plotted along with the respective
CD8A expression levels after normalization to b-actin. A pooled mix of equal amounts of all samples served as calibrator (Cal). (c) Pearson
correlation coefficient of CD8A-GPC6 expression levels. The correlation is significant (𝑝 = 0.0067). (d) The relative expression of GPC6 in 7
ovarian cancer cell lines was estimated by qPCR (normalized to b-actin). (e-f) Immunohistochemistry of GPC6 expression in representative
early stage ovarian tumor samples. (e) Negative expression of GPC6 protein in the tumor sample 314 with low mRNA levels of the respective
gene (see 1(b)). (f) Strong expression of the GPC6 protein in the 408 sample with also highmRNA levels (see 1(b)). Magnification (e-f): ×400.
Columns: mean, bars: SEM.
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Figure 2: TMEM132D is overexpressed in TIL+ early stage ovarian cancer and its expression correlates positively with CD8+ T-lymphocyte
infiltration. (a) TMEM132D was overexpressed in the TIL+ ovarian cancer sample as visualized by fluorescent ADDER (band indicated by
an arrow). (b) The expression of GPC6 was quantified by qPCR in samples derived from 38 stage I-II ovarian cancer patients. The relative
expression of TMEM132Dwas plotted along with the respective CD8A expression levels after normalization to b-actin. A pooled mix of equal
amounts of all samples served as calibrator (Cal). (c) Pearson correlation coefficient of CD8A-TMEM132D expression levels. The correlation
is significant (𝑝 = 0.0067). (d) The relative expression of TMEM132D in 7 ovarian cancer cell lines was estimated by qPCR (normalized to
b-actin). (e-f) Immunohistochemistry of TMEM132D expression in representative early stage ovarian tumor samples. (e) Negative expression
of TMEM132D protein in the tumor sample 408 with low mRNA levels of the respective gene (see 2(b)). (f) Very strong expression of the
TMEM132D protein in the 314 sample with also high mRNA levels (see 2(b)). Magnification (e-f): ×400. Columns: mean, bars: SEM.
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Table 1: Clinicopathologic characteristics of the stage I/II ovarian cancer patients.
Characteristic 𝑁 (%)
All stages,𝑁 = 35 Stage I,𝑁 = 28 (80%) Stage II,𝑁 = 7 (20%)
Age at diagnosis
Median/mean 59/57.63 59/56.86 59/60.71
Range (34–83) (34–78) (51–83)
Grade
0 2 (5.7) 2 (7.1)
1 12 (34.3) 10 (35.7) 2 (28.6)
2 8 (22.9) 5 (17.9) 3 (42.9)
3 13 (37.1) 11 (39.3) 2 (28.6)
Histological subtype
Serous 11 (31.4) 9 (32.1) 2 (28.5)
Endometrioid 20 (57.2) 16 (57.2) 4 (57.2)
Clear-cell 4 (11.4) 3 (10.7) 1 (14.3)
Debulking status
Optimal 34 (97.1) 28 (100) 6 (85.7)
Suboptimal 1 (2.9) 1 (14.3)
Response to therapy
CRa 33 (94.3) 27 (96.4) 6 (85.7)
PDb 2 (5.7) 1 (3.6) 1 (14.3)
Survival
Ovarian cancer deaths 6 (17.1) 4 (14.3) 2 (28.5)
Total number of deaths 6 (17.1) 4 (14.3) 2 (28.5)
aComplete response.
bProgressive disease.
of GPC6 and TMEM132D at protein level in the cancer
cells, we performed immunohistochemistry in sections from
representative tumor samples with either high or low mRNA
levels of GPC6 and TMEM132D as categorized by qPCR
(Figures 1(e)-1(f) and 2(e)-2(f)). As depicted in Figure 1(e),
the tumors with low mRNA levels of GPC6 also showed
negative expression of the gene at protein level. On the
contrary, high expression of the GPC6 protein was observed
in tumors with high mRNA levels of the gene. Consistently,
the tumors with low mRNA levels of TMEM132D showed
little expression at protein level, whereas the tumorswith high
levels of TMEM132D mRNA also showed strong expression
at protein level. In conclusion, GPC6 and TMEM132D could
serve as potent markers of CD8+ T-cell infiltration in early
stage ovarian cancer.
3.2. The mRNA Levels of GPC6 and TMEM132D Correlate
with Patients’ Overall Survival in Early Stage Ovarian Cancer.
In order to evaluate the survival predictive value of GPC6
and TMEM132D mRNA levels in early stage ovarian cancer,
we performed a retrospective clinical analysis of the above-
studied stage I-II ovarian cancer patients. Patients x1, x2, and
x3 were excluded from this analysis due to unavailability of
complete data. The clinicopathologic characteristics of the
35 early stage ovarian cancer patients are shown in Table 1.
Twenty-eight patients (80%) presented stage I ovarian cancer
and seven patients (20%) were stage II. The majority of
the patients had endometrioid and clear-cell ovarian tumors
(Table 1). All of the clear-cell and more than half of the
endometrioid tumors (55%) were high grade. Similarly, about
54% of the serous tumours were also high grade. The median
age at diagnosis for all patients was 59 years, while the mean
overall survival among the entire cohort was 189 months
(95% C.I. 164–213, Table 2). Six patients (17.14%) deceased
due to the disease during the study period. There were no
statistically significant differences in survival among the two
stages or the histological subtypes of the disease (data not
shown).
As about 25% of the tumors exhibited abundant T-
cell infiltration and both GPC6 and TMEM132D correlated
with infiltration, the 75th percentile median mRNA levels
of GPC6 (1.8 relative expression units) or TMEM132D (5.0
relative expression units) were selected as the cut-off values
to subdivide the patient cohort into two groups: patients
with high and patients with low mRNA levels of the relevant
gene. There was no significant age difference among the two
groups of patients, neither in the case of GPC6 subdivision
nor in the case of TMEM132D subdivision. The presence of
high levels of GPC6 and TMEM132D was also analysed in
relation to stage, grade, and type of the disease. Statistically
significant differences were not observed for themRNA levels
of the two genes among different stages, grades, or types of
tumors (Tables S1 and S2 in SupplementaryMaterial available
online at http://dx.doi.org/10.1155/2015/712438). Kaplan-Meir
curves were calculated for the mRNA levels in order to
assess whetherGPC6 or TMEM132D levels were predictive of
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Table 2: Survival characteristics of patients related to their tumoral GPC6 and TMEM132DmRNA levels.
All GPC6 mRNA levels TMEM132D mRNA levels GPC6/TMEM132D mRNA levels
Low High Low High Both low High GPC6 and/or TMEM132D
N (%) 35 28 (80) 7 (20) 26 (74.3) 9 (25.7) 22 (62.9) 13 (37.1)
Survival
5-year survival (%) 91.34 ± 4.78 88.73 ± 6.13 100 88.29 ± 6.36 100 85.45 ± 7.78 100
10-year survival (%) 84.69 ± 6.34 80.06 ± 8.04 100 78.73 ± 8.55 100 73.62 ± 10.27 100
Overall survival (months)
Mean ± SE 189 ± 12 179 ± 15 Undefineda 152 ± 13 Undefineda 144 ± 15 Undefineda
95% C.I. 164–213 149–209 — 126–177 — 114–174 —
Death cases (%) 6 (17.14%) 6 (21.4) 0 (0) 6 (23.1) 0 (0) 6 (27.3) 0 (0)
𝑝 value (log-rank test) 0.214 0.099 0.032
aAll subjects alive.
survival (Figures S1(a) and (b), resp.). As shown inTable 2, the
analysis suggested a strong trend towards increased survival
for patients with high mRNA levels of GPC6. Over twenty
percent (21.4%) of the patients with low levels deceased due
to the disease. Similar results were obtained for TMEM132D.
Interestingly, all patients with high mRNA levels of GPC6 or
TMEM132D were still alive at the end of the study.
We then asked whether the expression of both GPC6 and
TMEM132D genes in combination correlated with survival.
We divided the patients into 2 groups based on the combined
expression of GPC6 and TMEM132D: (i) patients with low
levels of both genes (𝑛 = 22, 62.9%) and (ii) patients with
high mRNA levels of GPC6 and/or TMEM132D (𝑛 = 13,
37.1%). No significant difference in age was observed among
the two groups. Patients with lowmRNA levels of bothGPC6
and TMEM132D had a mean overall survival of 144 months
(95% C.I. 114–174). Furthermore, 27.3% of the patients with
low mRNA levels deceased due to the disease (Table 2). On
the contrary, all the patients with high mRNA levels of GPC6
and/or TMEM132D were alive until the last follow-up (or
the end of the study). In conclusion, as shown in Figure 3,
high mRNA levels of GPC6 and/or TMEM132D correlate
significantly with increased overall survival (𝑝 = 0.032) in
early stage ovarian cancer.
Although CD8A is a classic established marker of T-cell
infiltration in ovarian cancer, in our cohort of patients, the
prognostic value ofCD8AmRNA levels was statistically weak
(𝑝 = 0.805) possibly due to the small size of the sample
and the low number of deaths. However, in the same cohort
of patients, high mRNA levels of GPC6 and/or TMEM132
associated significantly with increased survival.
Taken together, our data indicate GPC6 and TMEM132D
as potential markers for CD8+ T-lymphocyte infiltration,
favorable prognosis, and survival benefit in early stage ovar-
ian cancer.
4. Discussion
It is well established that the expression of CD8A at the
transcriptional level is a reliable indicator of CD8+ T-cell
infiltration in ovarian cancer [9, 19]. In this study, we
documented an association between the expression of GPC6
High GPC6 and/or TMEM132D
Low GPC6 and TMEM132D
Log-rank p = 0.032
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Figure 3: High mRNA levels of GPC6 and/or TMEM132D corre-
late with increased overall survival of early stage ovarian cancer
patients. Kaplan-Meier survival curves calculated for both GPC6
and TMEM132D mRNA levels. Patients were divided into two
groups: (i) patients with low mRNA levels of both GPC6 and
TMEM132D (cut-off points 1.8 and 5, resp.) and (ii) patients with
GPC6 and/or TMEM132D high levels. Patients with high mRNA
levels of GPC6 and/or TMEM132D exhibit a favorable overall
survival (𝑝 = 0.032).
and TMEM132D with CD8+ T-lymphocyte infiltration and
favorable prognosis in early stage ovarian cancer. Both genes
were found to be differentially expressed in TIL+ versus the
TIL− early stage ovarian cancer [19]. Here we validated by
qPCR analysis in a larger group of stage I/II patients (𝑛 = 38)
that themRNAexpression levels of the two genes significantly
correlated with the mRNA levels of the T-cell infiltration
marker CD8A. More importantly, we showed that early stage
ovarian cancer patients with highmRNA levels of at least one
of the two genes, GPC6 and TMEM132D, exhibited increased
overall survival compared to patients with low levels of both
genes.
Our results suggest an involvement of GPC6 in the
biology of lymphocyte infiltration in early stage ovarian
8 BioMed Research International
tumors. GPC6 encodes for Glypican-6, a 62.7 kDa heparan
sulfate proteoglycan [21, 22]. Glypicans are proteins bearing
glycosaminoglycan chains. There are six members of the
family (GPC1–GPC6) in mammals, with GPC6 being a
close homologue to GPC4 (64% identity). Glypicans are
attached to the outer surface of the membrane through a
glycosylphosphatidylinositol (GPI) anchor but can also be
released to the extracellular space [23, 24]. Their heparan
sulfate glycosaminoglycan chains are at the C-terminus of
the protein, close to the membrane, and are thought to
facilitate the interaction of glypicans with other molecules
and receptors of the membrane. It has been shown that
glypicans may regulate Hedgehog, Wnt, BMP, and FGF sig-
naling pathways [24]. Interestingly, inDrosophila the released
glypicans are involved in the transport of Wnts, Hhs, and
BMPs by creating a morphogen gradient [25]. Furthermore,
GPC6 promotes invasive migration of breast cancer cells
through a noncanonical Wnt5A signaling pathway [26]. In
particular, NFAT induces the expression of GPC6 which
in turn inhibits canonical Wnt and b-catenin signaling and
activates Wnt5A signaling that results in activation of JNK
and p38𝛼 kinases [26]. Further studies are required in order
to shed light on the role of GPC6 in ovarian cancer and
the mechanism of CD8+ T-lymphocyte infiltration. It is
reasonable to anticipate that GPC6 may mediate intercellular
interactions with immune cells or that it may be involved in
shaping a chemokine gradient, necessary for the CD8+ T-
lymphocyte infiltration.
On the other hand, little is known about the biolog-
ical role of TMEM132D. Polymorphisms in TMEM132D
gene have been associated with panic disorder [27, 28].
TMEM132D encodes a single-pass type I transmembrane
protein initially discovered in mature oligodendrocytes.
TMEM132D expression is detectable in brain, lung, pancreas,
and testis, but intriguingly not in normal ovaries [29]. Thus,
it is possible that the expression of TMEM132D is induced
in ovarian cancer and by an unknown mechanism becomes
implicated in CD8+ T-lymphocyte infiltration. Based on the
presence of TMEM132D on the plasma membrane surface,
one could hypothesize an involvement in cell-cell interactions
or intercellular signaling mechanisms that could be impli-
cated with T-cell recruitment.
According to our results, early stage ovarian cancer
patients with low mRNA levels of GPC6 and TMEM132D
exhibit significantly reduced overall survival compared to
patients with high levels of GPC6 and/or TMEM132D.
Therefore, we suggest that GPC6 and TMEM132D mRNA
levels could serve as markers of CD8+ T-cell infiltration
and survival prognosis in early stage ovarian cancer. For
example, monitoring tumoralGPC6 and TMEM132DmRNA
levels could facilitate the identification of early stage ovarian
cancer patients at high risk. Our conclusions underscore the
necessity to elucidate the molecular mechanism of GPC6
and TMEM132D involvement in T-cell infiltration and their
impact on cancer progression and also highlight their possi-
ble importance as putative diagnostic/therapeutic targets.
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